New data shows TECVAYLI plus DARZALEX FASPRO significantly improves survival outcomes for patients with relapsed/refractory multiple myeloma, setting the stage for a new standard of care.
Eli Lilly has announced positive late-stage trial results for orforglipron, its investigational once-daily oral GLP-1 drug. In Phase 3 studies, orforglipron demonstrated superior blood sugar control and significant weight loss in adults with type 2 diabetes, outperforming other existing medications. These results position it as a potential new standard of care and a convenient oral alternative to injectable treatments.
Johnson & Johnson announced strong third-quarter 2025 financial results, with reported sales increasing by 6.8% to $24.0 billion. The company’s Innovative Medicine and MedTech divisions both contributed to this growth. As a result of this strong performance, Johnson & Johnson has raised its full-year 2025 sales guidance.
Leading pharmaceutical companies including Roche, Eli Lilly, AbbVie, and Gilead/Kite are set to present significant new data from their oncology pipelines at the ESMO Congress 2025 in Berlin (Oct 17-21). Presentations will highlight advancements in targeted therapies, ADCs, and cell therapy for multiple cancer types, focusing on key drugs like Tecentriq, Verzenio, and Trodelvy.
AstraZeneca has announced a landmark agreement with the US government to significantly cut the cost of prescription medicines for millions of American patients via the Most-Favored-Nation (MFN) drug pricing model. The deal includes up to 98% discounts on key respiratory drugs for direct patient purchases and a $50 billion commitment to US manufacturing and R&D, securing a three-year exemption from threatened tariffs.
AstraZeneca announced a record $4.5 billion investment in its new Virginia manufacturing facility. The expansion will create 3,600 jobs and bolster the production of life-saving medicines, including next-generation ADC cancer treatments and metabolic drugs.
Johnson & Johnson announces that the U.S. FDA has approved SIMPONI® (golimumab) for the treatment of moderately to severely active ulcerative colitis in children weighing at least 15 kg. This approval provides a new subcutaneous treatment option for younger UC patients.
Eli Lilly and Company announced a significant milestone for Omvoh (mirikizumab-mrkz), which is now the first and only IL-23p19 antagonist to demonstrate four years of sustained, corticosteroid-free comprehensive patient outcomes for individuals living with ulcerative colitis (UC).
A landmark study by Ohio State scientists reveals the underlying mechanism of cancer immunotherapy failure: a fatal “proteotoxic shock” or protein quality control collapse (TexPSR) in T-cells. This newly identified stress pathway overwhelms immune cells with misfolded proteins, disabling their tumor-fighting function. Crucially, blocking the TexPSR pathway in preclinical models restored T-cell function and made immunotherapy markedly more effective, offering an entirely new target for cancer treatment development.
AbbVie has broken ground on a $70 million expansion of its Bioresearch Center in Worcester, MA, a key part of its $10 billion U.S. investment plan. The project will add new manufacturing suites and labs to increase domestic production of complex biologic medicines for immunology and oncology, creating new jobs and bringing key manufacturing capabilities from Europe to the United States.
